Skip to main content
Gilead10-Q: Bookings decline

Veklury sales decline 81% in Q2 2026 due to lower COVID-19 hospitalizations

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Veklury product sales decreased 81% to $23 million for the second quarter of 2026 compared to $121 million in the prior-year period due to lower COVID-19 hospitalization demand. The sharp contraction highlights shifting virology demand and may lead Gilead to shift commercial focus toward expanding HIV and liver disease portfolios.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

Gilead 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

Veklury product sales decreased 81% and 60% to $23 million and $167 million for the three and six months ended June 30, 2026, respectively, compared to the same periods in 2025, primarily due to lower rates of COVID-19-related hospitalizations.

sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htmRead the full source

Other signals in this filing (5)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Bookings decline

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$23M (Veklury product sales for the three months ended June 30, 2026)
Percent
-81% (decline in Veklury sales compared to same period in 2025)

Details

CIK
882095
Accession number
0000882095-26-000031
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
Sales effectiveness tools
Signal category
Revenue

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
bookingsDecline

Use this data

Get every 10-Q signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/dffb170a-c39d-484f-893f-3cb1a1a4e647 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "dffb170a-c39d-484f-893f-3cb1a1a4e647",
  "signal_type": "sec-10q",
  "signal_subtype": "bookingsDecline",
  "detected_at": "2026-11-09T06:33:00.008+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "detail": "Veklury product sales decreased 81% to $23 million for the second quarter of 2026 compared to $121 million in the prior-year period due to lower COVID-19 hospitalization demand. The sharp contraction highlights shifting virology demand and may lead Gilead to shift commercial focus toward expanding HIV and liver disease portfolios.",
    "metrics": {
      "pct": -0.81,
      "timeframe": "current_quarter",
      "pct_context": "decline in Veklury sales compared to same period in 2025",
      "dollar_context": "Veklury product sales for the three months ended June 30, 2026",
      "dollar_millions": 23
    },
    "quarter": "Q2",
    "summary": "Veklury sales decline 81% in Q2 2026 due to lower COVID-19 hospitalizations",
    "excerpts": "Veklury product sales decreased 81% and 60% to $23 million and $167 million for the three and six months ended June 30, 2026, respectively, compared to the same periods in 2025, primarily due to lower rates of COVID-19-related hospitalizations.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "Sales effectiveness tools",
    "signal_category": "revenue"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.